$6 doesn't make any sense.
$6 = $2.5B market cap = roughly $650M in revenues @ a 3.5x sales valuation.
If we don't think we will ever have peak revenues better than $650M, then we are screwed.
$10 should be the absolute worst case. That implies roughly $1B in peak worldwide revenues. $15 would imply $1.6-1.8B.
And this would be base-case, with just straight-up Vascepa. If we can enhance that with future indications and new formulations, then it may look even better.
I think $12-15 is VERY reasonable.
My calc is VERY rough. There's lots of things that really go into that number (which really would be based on DCF calcs). But keep in mind, the advantage that a BP would have with selling Vascepa is that it could be sold alongside other drugs in their arsenal. This isn't some rare disease we are treating that would need a dedicated sales force. So a BP can realize huge efficiencies with the sales process, so the "contribution margins" (our new favorite term! LOL!) from Vascepa could be massive.
For those that would be "happy" with Denner dumping for 5 bucks or 7 bucks or whatever, that's absolutely crazy.
A lot of you are anchoring your target prices to some arbitrary figure based on historical stock price, or whatever you bought it for, or what Denner bought it for.
News 
Market Data 
Discover 
AI
